September 16, 2019 8:14pm

The cell and gene therapy sector was a safe haven in today’s market

Keep it that way, we NEED read-outs of positive clinical data

Another I told you so, Adverum (ADVM +$0.51) would pop!

As the leading voice of cell and gene therapy investors; I am not always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and operating roles) with the gray hair and a readership g with extrapolations to prove it!


 

There are a variety of end uses to sector forecasts; the most prominent, they are used to protect your portfolio’s life and value.

 

Markets and indexes:

  • The Dow closed down -142.70 points or -0.52% to 27,076.82;
  • The S&P closed down -9.43 points or -0.31% at 2,997.96;
  • The NASDAQ was down -23.15 or -0.28% to 8,153.54;

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday the IBB closed up +0.94% while the XBI also closed up +1.44%
  • Friday the IBB closed up +0.05% while the XBI also closed down -0.23%

 

Henry’omics:

Cell and gene therapy stocks spiked upward  while the market’s three major indexes lost ground on Monday after weekend attacks on Saudi Arabia's oil facilities added to investors' concerns about geopolitical risk and a slowing global economy./

Reiterating, “I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Market breadth is improving as “our” universe’s stocks begin to latch onto upward mobility.

Incremental moves are needed supported by data otherwise machines and algorithms will plunder any upsides!

 

The advance/decline line scenario of 45 covered companies:  

  • Monday the close was positive with an Advance/Decline (A/D) line of 31/11 and 1 flat and 2 acquired;
  • Friday the close was negative with an A/D Line of 18/22 and 3 flats and 2 acquired;

 

Decliners:

  • Ionis Pharmaceuticals (IONS -$1.07 after Friday’s -$0.68 after Thursday’s +$2.05, Wednesday’s +$2.04, Tuesday’s+$2.67 and last Monday’s -$1.63);
  • Global Blood Therapeutics (GBT -$0.90);
  • uniQure (QURE -$0.57 after Friday’s -$1.08);
  • AxoGen (AXGN -$0.39);
  • Caladrius Biosciences (CLBS -$0.13);

Incliners:

  • ReNeuron (RENE.L +$10.00);
  • Sage Therapeutics (SAGE +$5.56 after Friday’s -$1.11);
  • Regenxbio (RGNX +$2.01 after Friday’s -$1.64 and Thursday’s +$2.18);
  • bluebird bio (BLUE +$2.01 after Friday’s +$1.74, Thursday’s +$2.03, Wednesday’s-$0.71 and last Tuesday’s +$2.14);
  • CRISPER Therapeutics (CRSP +$2.00);

 

The percentage (%) indicators: 

  • Monday’s range of the 32 upside was +0.03% (ONCE) to +8.82% (ADVM) while the 11 downside ranged from -0.23% (PSTI) to -5.26% (CLBS);
  • Friday’s range of the 18 upside was +0.40% (CLBS) to +8.25% (HSGX +$0.017) while the 22 downside ranged from -0.21% (BMRN) to -5.41% (ONVO);

 

Upside volume stats:  to compare

  • Monday: 6 out of the 32 upside had higher than the 3 month average volume;
  • Friday: 5 out of the 18 upside had higher than the 3 month average volume;

Downside volume stats:

  • Monday: 3 out of the 11 downside had higher than the 3 month average volume;
  • Friday: 6 out of the 22 downside had higher than the 3 month average volume;

 

0 flat with 2 acquired (AST & OSIR) and Spark Therapeutics’ (ONCE) acquisition by Roche still being delayed (SEPTEMBER?)

 

September’s sessions:

Monday closed POSITIVE with 11 decliners, 32 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 22 decliners, 18 advancers, 3 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 17 advancers, 0 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 10 decliners, 31 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 18 decliners, 25 advancers, 0 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 26 decliners, 16 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 11 decliners, 31 advancers, 1 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 22 advancers, 1 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 12 advancers, 2 flats and 2 acquired (AST & OSIR);

Monday was Labor Day

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.